A Phase 2 interventional study of AZD6234 and Placebo comparator in Obesity or Overweight, sponsored by AstraZeneca. Completed at 41 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index [BMI] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
The study will comprise of:
A screening period of maximum 28 days
A treatment period of 36 weeks
A follow up period after last dose of study drug
This study will consist of 4 cohorts. Approximately 231 eligible participants will be randomized to AZD6234 or placebo
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 262 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dose 1
Drug: AZD6234
Dose 2
Drug: AZD6234
Dose 3
Drug: AZD6234
Placebo - Dose matched with each Experimental arm
Drug: Placebo comparator
IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Placebo matching IMP dose injected subcutaneously, once a week.
Percent change in body weight from baseline to week 26
To determine whether AZD6234 is superior to placebo for weight loss
Time frame: 26 weeks
Weight loss ≥ 5% from baseline weight to week 26
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline
Time frame: 26 weeks
Weight loss ≥ 5% from baseline to week 36
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline
Time frame: 36 weeks
Weight loss ≥ 10% from baseline to week 36
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 10% from baseline
Time frame: 36 weeks
Percent change in body weight from baseline to week 36
To determine whether AZD6234 is superior to placebo for weight loss
Time frame: 36 weeks
Absolute change in body weight (kg) from baseline to week 26 and week 36
To determine whether AZD6234 is superior to placebo for absolute weight loss
Time frame: week 26 and week 36
AZD6234 plasma concentrations
To characterise the PK of AZD6234
Time frame: Week 43
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Sap
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca